Search | Korea Science

Application of Stress Hormones in Saliva in Research of Orofacial Pain Related with Stress (스트레스와 관련된 구강안면통증의 연구에 있어서 타액내의 스트레스호르몬의 활용)

Ryu, Ji-Won;Yoon, Chang-Lyuk;Ahn, Jong-Mo
- Journal of Oral Medicine and Pain
- /
- v.32 no.2
- /
- pp.201-210
- /
- 2007
Many diseases occur by stress or effect of stress. The basis for using hormones in research of stress is the observation that most systems in the body show changes during stress and that hormonal markers in these changes are related with stress. Conceptually, the central role of sympathetic nervous system(SNS) and hypothalamus-pituitary-adrenal(HPA) axis activity in stress provides copious justification for measuring hormonal changes. Catecholamines like epinephrine and norepinephrine, cortisol, testosterone and growth hormone and so on show sensitive reaction to stress. The major advantage of salivary sample to stress research is that its sampling technique can be performed in non-stressful conditions and without physical restraint and ethical problems. Because hormone levels in saliva is a good reflection of hormone levels in plasma, application of stress hormones in saliva is very useful for research of orofacial pain related with stress.
PDF KSCI

The comparison of predicted adult height change and height gain after gonadotropin-releasing hormone agonist and combined growth hormone treatment in girls with idiopathic central precocious puberty (진성 성조숙증으로 진단 받은 여아에서 gonadotropin-releasing hormone agonist 단독치료 및 growth hormone의 병합치료 시 예측 성인키의 변화 및 성장 획득의 비교)

Seo, Ji-Young;Yoon, In-Suk;Shin, Choong-Ho;Yang, Sei-Won
- Clinical and Experimental Pediatrics
- /
- v.49 no.3
- /
- pp.305-311
- /
- 2006
Purpose : GnRH analogues(GnRHa) are used to treat central precocious puberty(CPP). However, in some patients, the GV decrease is so remarkable that it impairs predicted adult height(PAH); and there fore, the addition of growth hormone(GH) is suggested. We analysed the growth changes during two years and final adult height(FAH) in girls with idiopathic CPP treated with combined therapy, compared with those of girls treated with GnRHa alone. Methods : For the analysis, we classified the patients, who was treated for longer than two years, into three groups depending on the initial PAH and combination of GH; PAH_L, treated with GnRHa and PAH less than midparental height(MPH) - 5 cm. PAH_H, treated with GnRHa and PAH greater than MPH - 5 cm. GnRHa＋GH, combined GH treatment, regardless of PAH before treatment. We analysed the GV and PAH change during the first two years and FAH. Results : In PAH_L, the PAH(SDS) at first year of therapy was significantly increased to $153.5{\pm}6.5cm(-1.4{\pm}1.3)$ from $149.7{\pm}6.4cm(-2.1{\pm}1.3)$ before treatment(P=0.004). In PAH_H, there was no significant increase in PAH during the two years of treatment. During the first year of combination of GH and GnRHa, GV and PAH increased significantly. We observed significant increases in FAH, comparing to the initial PAH in the PAH_L and GnRHa＋GH groups. The height gains(FAH - initial PAH) were significantly higher in the PAH_L and GnRHa＋GH groups than that in the PAH_H group. Conclusion : This study suggests the FAH and height gains are improved in patients, whose predicted adult height before treatment was shorter than those with higher predicted adult height, with the treatment of GnRHa alone or in combination with GH. GH could not improve the final adult height, but compensated the growth in patients whose growth velocity was decelerated by GnRHa alone.
PDF KSCI